ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD

Rosen Law Firm is urging investors in Aardvark Therapeutics (AARD) to join a securities class action lawsuit with an October 13, 2026 deadline for lead plaintiff claims. The lawsuit alleges that defendants made materially false statements about the safety and prospects of their drug ARD-101, and failed to disclose material adverse facts about the company's business and operations.

09/08/2026, 9:27 PM • GlobeNewswire

Deadline Alert: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Aardvark Therapeutics faces a securities fraud class action lawsuit covering the period February 10, 2025 to May 14, 2026. The company voluntarily paused its Phase 3 HERO trial in February 2026 due to cardiac safety concerns, causing a 56.2% stock decline. In May 2026, the FDA placed a full clinical hold on the drug ARD-101, resulting in a further 32.1% stock drop. Investors who suffered losses are urged to file lead plaintiff motions by October 13, 2026.

09/07/2026, 3:40 PM • GlobeNewswire

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD

Rosen Law Firm is urging investors who purchased Aardvark Therapeutics securities during its IPO on February 13, 2025 or between February 13, 2025 and May 14, 2026 to join a securities class action lawsuit. The lawsuit alleges that defendants made materially false and misleading statements about the safety and prospects of ARD-101, with an October 13, 2026 deadline to serve as lead plaintiff.

09/05/2026, 12:34 PM • GlobeNewswire

Deadline Alert: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Aardvark Therapeutics faces a securities fraud class action lawsuit covering the period February 10, 2025 to May 14, 2026. The company voluntarily paused its Phase 3 HERO trial in February 2026 due to cardiac safety concerns, causing a 56.2% stock decline. In May 2026, the FDA placed a full clinical hold on the drug ARD-101, resulting in a further 32.1% stock drop. Investors are urged to file lead plaintiff motions by October 13, 2026.

09/01/2026, 4:00 PM • GlobeNewswire

ROSEN, A LONGSTANDING LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD

Rosen Law Firm is reminding investors in Aardvark Therapeutics, Inc. of an October 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the safety and prospects of its drug ARD-101, and failed to disclose material adverse facts about the company's business and operations.

08/30/2026, 7:07 PM • GlobeNewswire

Important Notice to Long-Term Shareholders Aardvark Therapeutics, Inc. (NASDAQ: AARD); Flotek Industries, Inc. (NYSE: FTK); GoDaddy Inc. (NYSE: GDDY); and Hub Group, Inc. (NASDAQ: HUBG); Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office announced investigations into shareholder claims against four companies: Aardvark Therapeutics for allegedly misleading statements about drug safety leading to 56% stock decline; Flotek Industries for misrepresentations regarding a terminated Puerto Rico power project; GoDaddy for failing to disclose impact of promotional pricing on bookings; and Hub Group for material financial statement misstatements. Long-term shareholders may pursue corporate reforms and compensation.

08/27/2026, 8:50 AM • GlobeNewswire

Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline

Hagens Berman has filed a securities class action lawsuit against Aardvark Therapeutics, alleging the company made materially false statements about the safety of its lead drug candidate ARD-101. The lawsuit covers investors who purchased stock during the IPO on February 13, 2025, through May 14, 2026. Aardvark voluntarily paused its Phase 3 HERO trial in February 2026 after discovering reversible cardiac observations, causing a 56% stock decline. The FDA subsequently placed a full clinical hold on ARD-101 in May 2026, resulting in an additional 32.1% stock drop. The lead plaintiff deadline is October 13, 2026.

08/25/2026, 6:55 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD

Pomerantz LLP is investigating potential securities fraud claims against Aardvark Therapeutics following the company's voluntary pause of its Phase 3 HERO trial in February 2026 due to cardiac safety concerns, and a subsequent FDA clinical hold placed on its ARD-101 drug in May 2026. The stock declined 56.2% following the initial announcement and an additional 32.1% after the FDA clinical hold.

05/26/2026, 4:58 PM • GlobeNewswire

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Aardvark Therapeutics (AARD) stock plummeted 56% on March 2, 2026, after the company paused its Phase 3 HERO trial for ARD-101 due to serious cardiac safety concerns. The abrupt halt contradicts prior investor assurances about the drug's safety profile, prompting Hagens Berman to investigate potential securities law violations and misleading disclosures about the drug's development and FDA communications.

05/14/2026, 2:20 PM • GlobeNewswire

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Aardvark Therapeutics (AARD) stock plummeted 56% on March 2, 2026, after the company paused its Phase 3 HERO trial for ARD-101, citing serious cardiac safety concerns. The abrupt halt contradicted prior investor assurances about the drug's safety profile, prompting shareholder rights firm Hagens Berman to investigate potential securities law violations and investor fraud.

04/09/2026, 7:26 PM • GlobeNewswire

Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm

Aardvark Therapeutics' stock plummeted 56.2% to $5.47 per share on March 2, 2026, after the company announced a voluntary pause of its Phase 3 HERO trial due to reversible cardiac observations in healthy volunteers at above-target therapeutic doses. The Portnoy Law Firm has initiated an investigation into possible securities fraud and may file a class action lawsuit on behalf of investors.

03/11/2026, 9:00 AM • GlobeNewswire

NOTICE TO DISREGARD -- Pomerantz LLP

Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. and FS KKR Capital Corp. The law firm is also issuing a retraction regarding a previous investigation notice about Ambarella, Inc.

03/05/2026, 12:55 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD

Pomerantz Law Firm is investigating potential securities fraud claims against Aardvark Therapeutics following the company's voluntary pause of its Phase 3 HERO trial due to reversible cardiac observations in safety monitoring. The announcement triggered a significant stock price decline of 56.2%, falling from $12.49 to $5.47 per share on March 2, 2026.

03/03/2026, 5:28 PM • GlobeNewswire

Stock Market Today: S&P 500, Dow, Nasdaq Futures Slide Amid US And Israel 'Operation Epic Furry' Against Iran— HKD, AARD, MDB In Focus (UPDATED)

U.S. stock futures fell sharply on Monday following geopolitical tensions with Iran, with the S&P 500, Dow Jones, and Nasdaq 100 all declining. The death of Iran's Supreme Leader and potential continuation of military strikes for weeks dampened market sentiment. Key movers included AMTD Digital surging 20% on strong revenue results, Aardvark Therapeutics plunging 53% after pausing a Phase 3 trial, and MongoDB dropping 2% ahead of earnings.

03/02/2026, 8:48 AM • Benzinga

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aardvark Therapeutics granted stock options to six new employees on February 9 and 11, 2026, totaling 152,338 shares with exercise prices of $13.48 and $12.67 respectively. The options vest over four years with standard 25% one-year cliff and monthly vesting thereafter, granted as inducement awards under the company's 2025 Inducement Equity Incentive Plan.

02/13/2026, 8:00 AM • GlobeNewswire